Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- IBL-Japan Concludes Codevelopment Agreement with IBL International for Diagnostic for Alzheimer Disease
July 24, 2012
- Kyowa Kirin Revises Business Forecast Upward on Steady Sales of Nesp
July 24, 2012
- Confident of Posting Sales of 100 Billion Yen with 3 Focal Products Including Teribone: Asahi Kasei Pharma President Asano
July 24, 2012
- Combination Drug Containing JR-051 to Be Developed: JCR
July 23, 2012
- Patent Cliff for Kipres Looms; Will Kyorin Continue to Stand Alone in Respiratory Disease Field?
July 23, 2012
- HBM Taking Advantage of Avian Biotechnology for Antibody Drug Discovery: President Toyoura
July 23, 2012
- Azilva Ranked No. 1 in Both HP, GP Markets for 2 Straight Months: Rep Track Survey
July 23, 2012
- Aricept Successor BACE Inhibitor Reduced Aβ in PI Studies: Eisai
July 20, 2012
- Inlyta as Standard Drug in Second-Line Treatment: Pfizer
July 20, 2012
- Sandoz Initiates Voluntary Recall of Carboplatin, Shipment Suspended
July 20, 2012
- Otsuka Starts PIII Trial of Rebamipide Ophthalmic Suspension in US
July 20, 2012
- Alfresa HD to Make Tokiwa Yakuhin Wholly-Owned Subsidiary
July 19, 2012
- OTC Market Decreases 0.4% to 611.5 Billion Yen in 2011: Fuji-Keizai
July 19, 2012
- Eisai Ties Up with Verastem for Generation of Novel Wnt Signal Inhibitors
July 19, 2012
- Chugai, Taisho File NDA for Novel Osteoporosis Treatment
July 19, 2012
- Chugai Opens Singapore Research Subsidiary, Aims to Produce Over 5 Antibody Candidates per Year
July 18, 2012
- Nippon Kayaku Initiates PIII Study of NK105 for Breast Cancer
July 18, 2012
- Chairman Humer of Roche Criticizes Drug Pricing Policy in Japan as“Extremely Negative”
July 18, 2012
- Nippon Kayaku Launches New Specification of Generic Kytril
July 18, 2012
- China to Overtake Japan as Second-Biggest Drug Market by 2016: IMS Health
July 18, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…